Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 28
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06676982 | Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma | ||
| NCT01082094 | Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure | ||
| NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | ||
| NCT01410331 | Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia | ||
| NCT06461351 | Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection | ||
| NCT04011293 | A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies | ||
| NCT03029338 | CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | ||
| NCT02975687 | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | ||
| NCT05667506 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | ||
| NCT06450067 | Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia | ||
| NCT06316791 | Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases | ||
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) | ||
| NCT04586478 | Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | ||
| NCT04232826 | A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma | ||
| NCT02115568 | Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203 | ||
| NCT01961726 | Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure | ||
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | ||
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | ||
| NCT06608342 | Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia | ||
| NCT04230473 | A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia | ||
| NCT06231368 | CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. | ||
| NCT04690192 | CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma | ||
| NCT04684147 | Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia | ||
| NCT06826430 | Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia | ||
| NCT01643590 | Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. | ||
| NCT04008524 | A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies | ||
| NCT02544204 | SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease | ||
| NCT07091370 | Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy |
